Skip to main content

Table 1 Analysis for the efficacy of CAP in the diagnosis of ≥S2 steatosis

From: Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis

Category

Subgroups

Case (n)

AUROC

SE

SP

DOR

I 2

Region

Europe + USA

4

0.7556

0.82 (0.77–0.86)

0.72 (0.65–0.78)

16.80 (4.55–61.99)

77.0%

Asia

4

0.8798

0.90 (0.83–0.92)

0.76 (0.69–0.81)

27.50 (16.36–46.25)

48.9%

Cutoff value

≥ Median

4

0.7839

0.81 0.76–0.85

0.75 0.69–0.80

13.41 4.93–36.46

77.9%

< Median

4

0.8799

0.92 0.87–0.95

0.72 0.65–0.79

35.10 17.43–70.67

53.1%

BMI

25–30 kg/m2

4

0.8619

0.90 (0.86–0.93)

0.74 (0.68–0.79)

29.88 (17.73–50.38)

44.3%

> 30 kg/m2

3

0.7869

0.79 (0.74–0.84)

0.73 (0.66–0.80)

9.43 (6.04–14.71)

80.5%

Age (mean)

≤ 45 year

3

0.8555

0.86 (0.80–0.91)

0.77 (0.69–0.84)

19.74 (10.95–35.58)

33.0%

>  45 year

5

0.8143

0.84 (0.80–0.88)

0.73 (0.67–0.78)

23.31 (6.86–79.26)

81.9%

  1. Abbreviations: AUROC area under the receiver operating characteristic curve, BMI body mass index, DOR diagnostic odds ratio, NR no reported, SE sensitivity, SP specificity